MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on February 23, 2006; DOI: 10.1124/mol.106.023721

0026-895X/06/6905-1510-1512$20.00
Mol Pharmacol 69:1510-1512, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Related Article
Right arrow All Versions of this Article:
mol.106.023721v1
69/5/1510    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in MolPharm
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, Z.
Right arrow Articles by Meier, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, Z.
Right arrow Articles by Meier, K. E.
Perspective

New Assignments for Multitasking Signal Transduction Inhibitors

Zhihong Zhang, and Kathryn E. Meier

Department of Pharmaceutical Sciences, Washington State University, Pullman, Washington

An article presented in this issue of Molecular Pharmacology (p. 1527) provides an intriguing example of how tyrosine kinase inhibitors can be put to many uses. In this article, the action of dasatinib (BMS-354825) is contrasted with that of imatinib, a kinase inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders. Both pharmacologic inhibitors target several tyrosine kinases, including Bcr-Abl and the platelet-derived growth factor receptor (PDGFR). Up to this point, the PDGFR has not been a primary therapeutic target for this class of agents. The work of Chen and colleagues shows that dasatinib is a particularly potent inhibitor of PDGFR and that the compound also targets Src kinase. The authors suggest that this combination of activities could be useful in the treatment of vascular obstructive diseases. Although a lack of absolute specificity has typically been regarded as a pharmacologic drawback, this study exemplifies how drugs with multiple molecular targets can potentially provide a very beneficial spectrum of therapeutic activities in multiple disease states.

Received February 21, 2006; accepted February 23, 2006

Address correspondence to: Dr. Kathryn E. Meier, Dept. of Pharmaceutical Sciences, P.O. Box 646534, Washington State University, Pullman, WA 99164-6534. E-mail: kmeier{at}wsu.edu


Related articles in MolPharm:

Potent Inhibition of Platelet-Derived Growth Factor-Induced Responses in Vascular Smooth Muscle Cells by BMS-354825 (Dasatinib)
Zhengming Chen, Francis Y. Lee, Kapil N. Bhalla, and Jie Wu
MolPharm 2006 69: 1527-1533. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
N. Kumar, R. Afeyan, H.-D. Kim, and D. A. Lauffenburger
Multipathway Model Enables Prediction of Kinase Inhibitor Cross-Talk Effects on Migration of Her2-Overexpressing Mammary Epithelial Cells
Mol. Pharmacol., June 1, 2008; 73(6): 1668 - 1678.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics